“Notably, Sarepta aims to broaden use of Elevidys to include patients who can no longer walk, a group whose disease is more advanced. That request “is more of a stretch,” Lugo wrote. “We would not be surprised if these patients are excluded from the expanded label.”
——————————/
Does that mean Non Ambulant DMD people won’t be able to access Elevidys ?
Leaves the door open for Atl 1102 to work its magic
Imo: FDA will do as Lugo wrote ..
FDA review re Sarepta 21/6/24 expanded gene therapy
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
